Triple-negative metastatic breast cancer with pituitary metastasis: symptom relief after debulking

Patient Info: Anonymized, Female, 60s | Stage IV

Biomarkers: Pituitary metastasis was triple-negative breast cancer with no HER2 amplification.

Metastatic Site: liver; bone/skull; right breast; left orbit/optic…

Transsphenoidal debulking relieved visual symptoms and 6-month MRI showed no pituitary recurrence, while known metastatic breast cancer at other sites remained part of her ongoing cancer course.

PubMed CentralRead more →

Stage IV Invasive Lobular Carcinoma: Nikoo's Patient Story

Patient Info: Nikoo, Female, 40s | Stage IV

Biomarkers: BRCA1/2 negative; PIK3 mutation reported on liquid biopsy

Metastatic Site: Peritoneal/abdominal lining; abdominal lymph nodes

Nikoo had Stage I invasive lobular breast cancer in 2003 and developed Stage IV metastatic recurrence in 2022 after about 19 years. As of October 2025, she was living with metastatic lobular breast cancer, had moved through multiple systemic options, and was participating in a Phase 1 clinical trial.

The Patient StoryRead more →

Stage IIIA triple-negative breast cancer with hypercalcemia from parathyroid adenoma

Patient Info: Anonymized, Female, 50s | Stage III

Biomarkers: ER-negative; PR-negative; HER2-negative

As of October 2025, evaluation for post-chemotherapy weakness showed no local breast cancer recurrence, no lymphadenopathy, and no bone metastases; hypercalcemia resolved after parathyroid adenoma removal while breast cancer care remained ongoing.

PubMed CentralRead more →

Stage II central breast cancer: oncoplastic breast-conserving surgery with hatchet and AICAP flaps

Patient Info: Anonymized, Female, 70+ | Stage II

She completed oncoplastic breast-conserving surgery and radiotherapy; 3 months after radiotherapy, the reconstructed breast remained soft with sufficient volume and favorable cosmetic results.

PubMed CentralRead more →

Stage IIA breast collision tumor: disease-free after surgery and adjuvant therapy

Patient Info: Anonymized, Female, 70+ | Stage II

Biomarkers: Two breast tumor parts were ER-positive; one HER2-low/negative and one HER2-positive. BRCA testing was suggested but not done.

Four years after surgery, she remained disease-free after mastectomy, adjuvant chemotherapy, HER2-targeted therapy, and endocrine therapy.

PubMed CentralRead more →

Luminal A solid papillary breast carcinoma with lung metastasis: mastectomy and lung resection, PET-CT clear

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: Initial breast tumor and lung metastasis were ER/PR positive, HER2 0

Metastatic Site: lung

About 40 days after lung surgery, PET-CT showed no abnormalities; the specialist recommended regular follow-up without additional antitumor drug therapy, and she was alive and in good condition.

PubMed CentralRead more →

Breast Cancer: Theresa's Survivor Story

Patient Info: Theresa, Female, 40s

Biomarkers: Hormone receptor-positive; exact receptors not fully specified

Theresa completed treatment for multiple cancers, including bilateral mastectomy/reconstruction for breast cancer and later excision plus 3 months of radiation for chest-wall recurrence. As of October 2025, she described being about 6 years out from the later recurrence, with no other cancer found on scans.

The Patient StoryRead more →

Hormone receptor-positive male breast cancer: spontaneous regression after biopsy and mastectomy

Patient Info: Anonymized, Male, 50s

Biomarkers: ER-positive; PR-positive; HER2-negative; p63 staining confirmed myoepithelial cells in residual benign cystic lesion

Mastectomy and axillary clearance showed no residual invasive carcinoma or carcinoma in situ, with clear margins; he recovered well and began adjuvant tamoxifen because of the original ER/PR-positive biopsy.

PubMed CentralRead more →

PT3N0 triple-negative breast carcinosarcoma: surgery, EC chemotherapy, radiation, disease-free at 26 months

Patient Info: Anonymized, Female, 50s

Biomarkers: Triple-negative breast carcinosarcoma. INI1 was retained

She was clinically free of disease at her last follow-up in April 2025, 26 months after treatment completion; December 2024 mammography showed no suspicious changes.

PubMed CentralRead more →

Paget disease, bilateral apocrine breast carcinomas, and primary breast follicular lymphoma after aromatase inhibition

Patient Info: Anonymized, Female, 70+

Biomarkers: Initial breast cancer was ER/PR-positive, HER2-negative. Later apocrine cancers were triple-negative with AR/ER-beta markers. Lymphoma had IgH::BCL2.

As of September 2025, she was alive 3 years after bilateral mastectomy and observation for Stage Ie follicular lymphoma, with no recurrence of either breast carcinoma or lymphoma.

PubMed CentralRead more →

Breast Cancer: Karin's Patient Story

Patient Info: Karin, Female, 50s

As of September 2025, Karin was living with recurrent incurable breast cancer, felt healthy and fit, and had chosen mastectomy with reconstruction, ovary removal, anti-hormone therapy, and complementary therapies after recurrence.

Stage 0 ER-positive DCIS: mastectomy without adjuvant therapy, followed by successful pregnancy

Patient Info: Anonymized, Female, 40s | Stage 0

Biomarkers: ER-positive; PgR-positive; HER2-negative; nuclear grade 2; comedo type; negative margins; no lymph node involvement

She completed surgical treatment for Stage 0 DCIS with negative margins and no lymph node involvement, avoided adjuvant therapy, resumed assisted reproductive treatment, and delivered a healthy male infant.

PubMed CentralRead more →

HER2-positive invasive lobular breast cancer in a transgender man: disease-free after multimodality care

Patient Info: Anonymized, transgender man, 70+ | Stage III

Biomarkers: HER2-positive invasive lobular breast cancer, ER/PR negative

Nearly 2 years after diagnosis, he remained disease-free while continuing survivorship care and counseling after discontinuing testosterone therapy.

PubMed CentralRead more →

Triple-negative breast pleomorphic adenocarcinoma: disease-free after mastectomy and one course of capecitabine

Patient Info: Anonymized, Female, 70+

Biomarkers: Triple-negative breast pleomorphic adenocarcinoma with PIK3CA mutation; markers supported the diagnosis.

As of September 2025, she had 2 years of disease-free survival after left total mastectomy, sentinel lymph node exploration, and 1 course of oral capecitabine.

PubMed CentralRead more →

Stage I Breast Cancer: Angela's Patient Story

Patient Info: Angela George, Female, 40s | Stage I

Biomarkers: Not explicitly reported; Herceptin was given

As of September 2025, Angela was approaching 5 years from her Stage I breast cancer diagnosis, had completed bilateral mastectomy, chemotherapy, Herceptin, and oophorectomy, and remained on daily estrogen-reducing medication with oncology visits every 6 months; the source does not explicitly state NED.

Cleveland ClinicRead more →

Invasive Ductal Carcinoma: Meghan's Patient Story

Patient Info: Meghan McLyman, female, 40s

Meghan was doing well and had returned to her normal life, teaching dance and volunteering as a peer mentor.

Dana-FarberRead more →

Stage IV Breast Cancer: Maria's Patient Story

Patient Info: Maria, Female | Stage IV

Metastatic Site: Bone (spine, clavicle, rib, thigh bone, scapula);…

Maria initially had a clean PET scan after chemotherapy, surgery, radiation, and targeted/endocrine therapy, but later developed Stage IV metastatic breast cancer involving multiple bone sites, with lung and cervical-region involvement also described. As of September 2025, she remained on treatment and did not have an available clinical trial option.

The Patient StoryRead more →

Stage IIA male breast cancer: chemotherapy, mastectomy, endocrine therapy, and benign adrenal nodule

Patient Info: Anonymized, Male, 50s | Stage II

Biomarkers: ER-positive; PR-positive; HER2-negative

Final breast cancer pathology was T1N1M0 / AJCC Stage IIA ER-positive, PR-positive, HER2-negative invasive ductal carcinoma; the suspicious adrenal lesion was removed in June 2025 and proved to be a benign adrenal adenoma.

PubMed CentralRead more →

Stage II Invasive Ductal Carcinoma: Charlotte's Survivor Story

Patient Info: Charlotte, Female | Stage II

Biomarkers: BRCA inherited mutation negative

As of September 2025, Charlotte had undergone bilateral mastectomy, removal of 2 lymph nodes, delayed wound healing, and radiation for Stage II invasive ductal carcinoma, and was focused on recovery and life after treatment.

Breast cancer survivorship complicated by fatal lymphedema-associated necrotizing soft tissue infection

Patient Info: Anonymized, Female, 50s

Biomarkers: Prior breast cancer: ER-positive, PR-positive, HER2-negative

She died after hospital-acquired pneumonia and acute respiratory failure during recovery from severe right-arm lymphedema-associated necrotizing soft tissue infection after prior breast cancer treatment.

PubMed CentralRead more →

Triple-negative breast cancer history with later chest wall sarcomatoid carcinoma treated by embolization, ablation, and chemotherapy

Patient Info: Anonymized, Female, 40s

Biomarkers: Initial breast cancer was triple-negative. Later chest-wall lesion was weak ER-positive, PR/HER2-negative

By February 2025, the treated chest wall lesion had decreased to about 13 x 7 mm after embolization, radiofrequency ablation, and albumin-bound paclitaxel plus cisplatin, with no peripheral or distant metastatic foci seen.

PubMed CentralRead more →

Stage IIIB male encapsulated papillary breast cancer: disease-free after surgery and adjuvant therapy

Patient Info: Anonymized, Male, 60s | Stage III

Biomarkers: ER-positive 100%; PR-positive 100%; HER2-negative / IHC 1+; p63 loss supported encapsulated papillary carcinoma; no neuroendocrine differentiation

Three years after diagnosis, he was clinically doing well without evidence of breast cancer recurrence after mastectomy, radiation, and tamoxifen.

PubMed CentralRead more →

Stage IV Breast Cancer: Iris's Patient Story

Patient Info: Iris, Female | Stage IV

Metastatic Site: Spine; liver; bone

As of August 2025, Iris was living with Stage IV metastatic breast cancer involving the spine, liver, and bones and was receiving systemic maintenance therapy with monthly injections and close monitoring.

Triple-negative node-positive breast cancer with complete pathologic response and benign nodal nevi

Patient Info: Anonymized, Female, 50s

Biomarkers: Triple-negative breast cancer; BRCA testing negative. Axillary melanocytic cells looked benign.

Pathology showed complete response in the breast, no residual breast carcinoma in the sampled specimen, and axillary nodal melanocytic proliferations interpreted as benign nodal nevi rather than metastatic melanoma or breast carcinoma.

PubMed CentralRead more →